960 x 350_41

Small and Large Molecule LC-MS

Accurately measuring and quantifying biomarkers in relevant matrices informs numerous aspects of clinical drug development. Biomarker assays can match patients to appropriate therapies and demonstrate a candidate drugs safety and efficacy, thus illuminating its potential for clinical and commercial success. Q2 Solutions offers a wide range of tailored and integrated liquid chromatography mass spectrometry services to support biomarker testing and quantitation, including LC/MS bioanalysis, LC/MS/MS analysis, hybrid LC-MS assays, small molecule LC/MS, and large molecule bioanalysis.

Our team has extensive experience developing and validating multiplex LC/MS assays of endogenous analytes (e.g., proteins, peptides, lipids) and small/large molecules and their metabolites. Q2 Solutions’ LC/MS/MS bioanalytical services are GLP and GCP compliant to support FDA, OECD, MHLW, and ICH standards.

Related Thought Leaders Insights

Hybrid Assays for Protein Bioanalysis

Authors: Steve Lowes, Ph.D., Senior Director, Bioanalytical Services Barry Jones, Ph.D., Director, LC-MS Biologics and Biomarkers Hybrid assays are powerful tools for protein bioanalysis of both...

Quantitative Assays for Peptides using LC-MS

We are one of the few bioanalytical laboratories successfully employing immunoprecipitation techniques, HRMS, and multi-dimensional liquid chromatography for the quantitation of peptide and protein...

Developing Assays for Novel Drugs

Novel drugs with complex design are becoming more common to treat difficult diseases. This insight brief, authored by Michael Brown, Ph.D., Senior Director, Immunoanalytical Services and Barry Jones,...